Inhibition of Angiogenesis, “Disappointments and Success”

  • Andreas Bikfalvi
Chapter

Abstract

Previous work by Judah Folkman had indicated that abnormal vascularization could be inhibited and that this could have a beneficial effect in pathological situations where vascularization was excessive. Many pharmacological substances are indeed capable of inhibiting the growth of endothelial cells, including synthetic molecules, plant extracts, and snake venoms.

References

  1. 132.
    Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18. https://doi.org/10.1146/annurev.med.57.121304.131306CrossRefPubMedGoogle Scholar
  2. 133.
    O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–285CrossRefGoogle Scholar
  3. 134.
    Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404–407. https://doi.org/10.1038/37126CrossRefPubMedGoogle Scholar
  4. 128.
    Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269(43):26988–26995PubMedPubMedCentralGoogle Scholar
  5. 129.
    Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573):435–439. https://doi.org/10.1038/380435a0CrossRefPubMedPubMedCentralGoogle Scholar
  6. 135.
    Kolata G (1998) Two drugs eradicate tumors in mice. New York Times, May 3Google Scholar
  7. 136.
    Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, Mundel T, Soubasakos M, Rubin K, Takeda T, Inoue M, Lawler J, Hynes RO, Hanahan D, Kalluri R (2011) Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A 108(24):9939–9944. https://doi.org/10.1073/pnas.1105041108CrossRefPubMedPubMedCentralGoogle Scholar
  8. 137.
    Murphy-Ullrich JE, Sage EH (2014) Revisiting the matricellular concept. J Int Soc Matrix Biol 37:1–14. https://doi.org/10.1016/j.matbio.2014.07.005CrossRefGoogle Scholar
  9. 138.
    Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328–335. https://doi.org/10.1016/j.bbrc.2005.05.132CrossRefPubMedGoogle Scholar
  10. 139.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. https://doi.org/10.1056/NEJMoa032691CrossRefPubMedPubMedCentralGoogle Scholar
  11. 140.
    Yancopoulos GD (2010) Clinical application of therapies targeting VEGF. Cell 143(1):13–16. https://doi.org/10.1016/j.cell.2010.09.028CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  • Andreas Bikfalvi
    • 1
  1. 1.Angiogenesis and Tumor Microenvironment LaboratoryUniversity of Bordeaux and National Institute of Health and Medical ResearchPessacFrance

Personalised recommendations